Clinical Trial Update: Safety and Efficacy Study of Transplantation of Autologous CD34+ Cells Transduced With the G2ARTE Lentiviral Vector Expressing the DCLRE1C cDNA in Artemis (DCLRE1C) Deficient Severe Combined Immunodeficiency Patients (ARTEGENE) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial update assessing autologous CD34+ cells transduced with the G2ARTE lentiviral vector expressing DCLRE1C cDNA in Artemis (DCLRE1C) defic…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Artemis Deficiency Associated Severe Combined Immunodeficiency

Drugs mentioned

• Autologous CD34+ hematopoietic stem/progenitor cells transduced with G2ARTE lentiviral vector expressing DCLRE1C cDNA (gene-modified autologous hematopoietic stem cells)
• G2ARTE Lentiviral Vector expressing DCLRE1C cDNA (G2ARTE lentiviral vector)

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: Artemis (DCLRE1C ) Deficient Severe Combined Immunodeficiency | Phase 1, Phase 2 | Status: RECRUITING